Tagged with ART

Novartis Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived in Turkey five months ago after working in China for two and a half years. Many executives in Turkey have…

Liba Murat Barlas, the longest serving board member for the Turkish Pharmaceutical Manufacturers Association, discusses the need for a new perspective in government-industry relations in the Turkish pharmaceutical industry, and the steps his firm has taken to find success in the meantime. What is the role of companies like Liba in…

generics Founded back in 1956, Laboratorios Keton is a small 100 percent Mexican company committed to provide high-quality contract manufacturing services to local as well as international drug makers. With more than 50 years of experience in the pharmaceutical industry, the founder discusses the company’s most important milestones, achieved under the…

local The general manager explains how vision behind the setting up of Grupo Rasch was to represent companies, primarily European and high-tech ones, in the manufacturing of drugs reveals and how his relationship with his business partner, Federico Scharrer, is the bedrock of the group’s success Grupo Rasch recently celebrated its…

Novartis The country president and general director of Novartis Morocco discusses the impact of the price cuts on the pharma market, the need to change the health culture in the country and the importance of Morocco as a hub.   As well as being the country president of Novartis Morocco, you…

Novartis Novartis strives for “creating solutions for patients that go beyond the pill”. The country head and next president of CANIFARMA discusses how the company is using new programs and technology to get innovation to patients, how the recent work of COFEPRIS is helping get drugs to patients faster and why…

Alexion Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put in place, and how Alexion is communicating with patients’ associations and medical community to raise awareness about ultra-rare diseases.  …

partnering The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about his current operations and his vision for the future.     Can you discuss the role that KIT plays today…

partnering Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at CHA Health Systems, outlines Korea’s strengths in healthcare and its forward-looking vision for the future.   You became chairman of…

innovation The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current scenario for local companies and outlines his ambitions for making Korea a global hub for innovation.   Since we met…

MSD Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the coming years.   2014 represents MSD’s 20th anniversary in Korea. How did the affiliate commemorate the occasion? In the current…

innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients.   You have had…